Sch23390 sch 23390 hydrochloride

For microinfusions, the concentrations used were 21.1 mM (6.25 μg μl⁻¹) for β-adrenoceptor antagonist propranolol [(S)-(−)-propranolol hydrochloride, 295.80 g mol⁻¹; Sigma-Aldrich), 3.1 mM (1 μg μl⁻¹) for D₁/D₅ receptor antagonist SCH23390 (SCH 23390 hydrochloride, 324.24 g mol⁻¹; Tocris) and 2% w/v for voltage-gated sodium channel blocker lidocaine (lidocaine hydrochloride monohydrate, 288.81 g mol⁻¹; Sigma-Aldrich). α₂-adrenoceptor agonist clonidine (clonidine hydrochloride, 266.55 g mol⁻¹; Sigma-Aldrich) was administered i.p. at a dose of 50 μg kg⁻¹ of body weight. We used 0.9% NaCl (saline) in H₂O as a vehicle and for control infusions. Both vehicle and drug solutions were stored in 100 μl aliquots at −20°C until use.